Cyproterone acetate or drospirenone containing combined oral contraceptives plus spironolactone or cyproterone acetate for hirsutism: Randomized comparison of three regimens

Kelekci K. H., Kelekci S., Yengel I., Gul S., Yilmaz B.

JOURNAL OF DERMATOLOGICAL TREATMENT, cilt.23, sa.3, ss.177-183, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23 Sayı: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.3109/09546634.2010.519766
  • Dergi Adı: JOURNAL OF DERMATOLOGICAL TREATMENT
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.177-183
  • Anahtar Kelimeler: combined oral contraceptives, cyproterone acetate, drospirenone, hirsutism, polycystic ovary syndrome, spironolactone, POLYCYSTIC-OVARY-SYNDROME, LONG-TERM TREATMENT, WOMEN, FLUTAMIDE, TRIAL, MANAGEMENT, EFFICACY
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

Objective: To compare the effectiveness of three different combinations of combined oral contraceptives (COCs) and anti-androgens in the treatment of hirsutism. Methods: A total of 134 women with moderate and severe hirsutism were randomly assigned to three treatment regimens: Group I received 30 mu g of ethinyl estradiol (EE)/3 mg of drospirenone (DRSP) plus 100 mg of cyproterone acetate (CPA) (n = 45); group II received 30 mu g of EE/3 mg of DRSP plus 100 mg of spironolactone (n = 44); and group III received 35 mu g of EE/2 mg of CPA plus 100 mg of CPA (n = 45), daily for 6 months. The decrease in the modified Ferriman-Gallwey hirsutism score (mFGS) was the main outcome measure. Results: The mean decrease in mFGS after 3 and 6 months of the treatment course was 26% and 49% in group I (both p < 0.01), 27% and 49% in group II (both p < 0.01), and 25% and 45% in group III (both p < 0.01), respectively, when compared with baseline. Although the mFGS was significantly decreased in all groups, there was no significant difference between groups. Conclusion: CPA or DRSP containing COCs in combination with CPA or spironolactone have similar effects for the treatment of hirsutism.